The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
about
Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosisEffect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID miceTwo 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii.Rifabutin is active in murine models of toxoplasmosisEffects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in micePhase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.Antiparasitic agent atovaquoneFeline ocular toxoplasmosis.Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazineAn ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondiiGenetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Rec
P2860
Q28343549-7A119251-2D01-4865-B2F4-30EE26AA1F2EQ28368166-A6000E25-A63D-44FE-9079-B3BF5293F33CQ28368883-3E00357B-70EC-4BEF-AB8F-2B85CF1F0EF2Q28378281-2E5FDD17-7AB4-42CF-9F8D-ACFD021DD83BQ28379020-A0F7EFAE-78AD-4724-8820-12115A4CC893Q33693150-11785B8F-210A-48B2-9B8B-52C94028A5B3Q34107885-53BC4701-2624-41E6-A869-A19409E3713EQ34276691-852782D4-EDA1-4AB3-8B14-0523A2780C7DQ35110989-8CAB5BA1-AF9B-49F5-9AE6-83F4A072C83BQ36028890-8F157E70-39DA-4DEF-B927-2909984D7AF4Q36258864-310B4EE6-CBA5-4976-BD7D-CFF2550F6D85Q39882492-A4AFCF68-AE54-49B3-9E6A-3172486599CDQ43952836-9F777E21-49E6-41B8-9969-8384BDC9EDE0
P2860
The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
The activity of atovaquone (56 ...... pyrimethamine or sulfadiazine.
@en
The activity of atovaquone
@nl
type
label
The activity of atovaquone (56 ...... pyrimethamine or sulfadiazine.
@en
The activity of atovaquone
@nl
prefLabel
The activity of atovaquone (56 ...... pyrimethamine or sulfadiazine.
@en
The activity of atovaquone
@nl
P2093
P356
P1476
The activity of atovaquone (56 ...... pyrimethamine or sulfadiazine.
@en
P2093
P304
P356
10.1093/INFDIS/167.2.494
P407
P577
1993-02-01T00:00:00Z